Clinical Trials Browser

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04263584 2024-01-05

COPA-R-CHOP

Phase 2 Unknown

62 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04803123 2023-12-21

Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL

Phase EARLY_PHASE1 Terminated

3 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04156828 2023-06-29

Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

Phase 1 Terminated

12 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03877055 2022-12-14

A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma

Phase 1/2 Completed

8 enrolled 7 charts

Lymphoid

Lymphoma, Mantle-Cell

NCT03128619 2022-09-26

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

Phase 1 Terminated

10 enrolled

Breast

Breast Neoplasms

NCT02535247 2022-07-08

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma

Phase 1/2 Terminated

17 enrolled 7 charts

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT03052933 2022-06-10

Copanlisib and Gemcitabine in Relapsed/Refractory PTCL

Phase 1/2 Completed

28 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT05010096 2022-05-27

BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors

Phase 1 Withdrawn

Tumor-Agnostic

Neoplasm Metastasis

NCT04155840 2022-04-11

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2 Terminated

1 enrolled 6 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03886649 2022-04-01

Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

Phase 1 Terminated

7 enrolled

LymphoidSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Dendritic Cell Sarcoma, Interdigitating

NCT02728258 2022-02-15

Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Phase 2 Completed

11 enrolled 12 charts

Carcinoma, Endometrioid

NCT02631590 2021-08-04

Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma

Phase 2 Completed

24 enrolled 11 charts

Gastrointestinal

Digestive System Neoplasms, Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

NCT02822482 2021-03-29

COPAN-ORL06

Phase 1/2 Terminated

11 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04233697 2020-08-13

Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma

Phase 1 Withdrawn

Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell

Clinical Trials

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

Copanlisib Plus Venetoclax in R/R DLBCL

Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

LCD

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL

A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

Study of Copanlisib and Ketogenic Diet

A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer

Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Alternative-C

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

COPA-R-CHOP

Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL

Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma

Copanlisib and Gemcitabine in Relapsed/Refractory PTCL

BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma

COPAN-ORL06

Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma